Western Europe to Represent Major Revenue Share of High Content Screening Market

(Newswire.net — June 28, 2017) New York City, New York — Increasing drug discovery processes globally and enhanced studies related to toxicity is likely to boost demand for innovative technology in the cell analysis. Moreover, surge in demand for high content screening surge in sales of high content screening instrument is fuelling growth of the global high content screening market in the upcoming years. A recent report compiled by Persistence Market Research reveals that the global high content screening market will reflect 6.1% CAGR growth during the forecast period.

Factors Propelling Growth of the Global Market

Drug discovery activities conducted and biological research have significantly contributed towards growth of the global high content screening market. Growing need for enhanced imaging, and increasing preference for secondary screening of toxicity studies is a factor significantly boosting growth of the global high content screening market in the upcoming years. Increasing research in the field of life science and increasing support from governments to research activities will boost sales of the HCS instruments.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/12931

Further, surge in number of pharmaceutical and biotech companies specializing in research will impact growth of the global high content screening market. Additionally, high-end and mid-end HCS instruments will account for relatively high revenue share. Emerging scalability analysis and automated cell technique will underscore profitable opportunities for researcher and manufacturers. Such factors will contribute towards growth of the global high content screening market. Growing prevalence of chronic diseases has revved up demand for risk assessment, which has revved up demand for HCS instruments globally.

Healthcare Application to Remain a Dominant Segment

Cell analysis and imaging equipment among other products will witness major demand in the global high content screening market during the predicted years. Software among other segments witnessed a steady Y-o-Y growth in 2016. The primary and secondary screening among other applications accounted for around US$ 459.4 million in terms of revenue in 2016. The HCS instrument is likely to witness relatively high consumption for primary and secondary screening between 2016 and 2025. In terms of revenue, the HCS instruments will represent a market share of 36%, and will witness 6% CAGR growth during the predicted years. Toxicity application among other segments will witness a relatively high CAGR of 7.1%, and is likely to account for US$ 406 million in terms of revenue. Healthcare and pharmaceuticals among other end users will represent a leading segment during the predicted years. Whereas, biotechnology will represent the second leading end user by the end of 2025.

Western Europe to Account for Major Revenue Share

Western Europe among other regions will account for nearly US$ 720.5 million, and for major revenue share by 2025-end. This region will register 6.1% CAGR during the predicted years. The high content screening market in North America will represent second major market position with a market share of around 31% by the end of 2025. The high content screening market in APAC is likely to witness major growth throughout 2025.

View Report Table of Contents, Figures, and Tables @ http://www.persistencemarketresearch.com/market-research/high-content-screening-market/toc

Market Player

Leading market players operating in the global market for high content screening include Becton, Thermo Fisher Scientific Inc., PerkinElmer Inc., Dickinson and Company (BD), Merck Millipore Corporation, GE Healthcare, Thorlabs Inc., Olympus Corporation, Sysmex Corporation, Danaher Corporation (Molecular Devices), Yokogawa Electric Corporation, and Sysmex Corporation.